Sensitivity to treatment and score bands of the Infants and Toddlers Dermatology Quality of Life questionnaire

Chernyshov, Pavel V; Marrón, S.E.; Boffa, Michael J.; Pustišek, Nives; Manolache, Liana; Kakourou, Talia; Cachia, Monique; Svyatenko, Tetiana; Koumaki, Dimitra; Chernyshov, A.V.; Aragonés, Lucía Tomás

doi:10.1016/j.jdin.2022.11.009

Cited by 6 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To avoid the problem of cross-cultural inequivalence, development and validation of the InToDermQoL were performed simultaneously in different national centers of the project [ 1 , 4 ]. Results of the international field tests confirmed internal consistency, test–retest reliability, convergent and discriminant validity, and sensitivity to treatment of the InToDermQoL questionnaire [ 4 , 5 ]. The first variant of score bands for the InToDermQoL questionnaire has been proposed [ 5 ].…”

Section: Introductionmentioning

confidence: 78%

“…Results of the international field tests confirmed internal consistency, test–retest reliability, convergent and discriminant validity, and sensitivity to treatment of the InToDermQoL questionnaire [ 4 , 5 ]. The first variant of score bands for the InToDermQoL questionnaire has been proposed [ 5 ]. The InToDermQoL was used to study QoL in children with seborrheic, allergic contact, and atopic dermatitis before and during the coronavirus disease 2019 (COVID-19) pandemic [ 6 ].…”

Section: Introductionmentioning

confidence: 78%

See 1 more Smart Citation

Responsiveness and Minimal Clinically Important Difference of the Infants and Toddlers Dermatology Quality of Life Questionnaire

Chernyshov,

Marron,

Koumaki

et al. 2023

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Background The Infants and Toddlers Dermatology Quality of Life (InToDermQoL) is the dermatology-specific proxy health-related quality of life (HRQoL) instrument for children from birth to 4 years. The aim of the present study was to confirm the responsiveness and establish minimal clinically important difference (MCID) for the InToDermQoL. Methods Parents of children with skin diseases were asked to fill in the InToDermQoL at the initial visit (T1) and subsequent consultation (T2). We hypothesized that correlations between change scores of the InToDermQoL and change scores of global assessment of clinical severity by dermatologists and by patients’ parents should be above 0.3. The receiver operating characteristic (ROC) curves method was also used for confirmation of responsiveness and determination of MCIDs of the InToDermQoL. The area under the ROC curve (AUC) was used as an indicator of responsiveness. Results Results of 442 patients were included. Correlations between change scores of age-specific versions of the InToDermQoL and change scores of global assessment of clinical severity by dermatologists and by patients’ parents were above 0.3 (0.46-0.74). AUCs for age-specific versions of the InToDermQoL were acceptable (above 0.7) or excellent (above 0.8). Estimated MCIDs for the InToDermQoL were as follows: 3 points of total score change for 0–11 months, 5 for 1–2 years and 3 or 4 for 3–4 years version. Estimated MCIDs for the InToDermQoL version for 1–2-year-old children was higher than MCIDs for the 3–4-year-old version despite the higher number of items in the latter. Therefore a MCID of 5 was recommended for both these versions. Conclusions Responsiveness for all age-specific versions of the InToDermQoL questionnaire was confirmed. MCIDs for the InToDermQoL are proposed as follows: 3-point change of the total score for age version 0–11 months and 5-point for the age versions 1–2 years and 3–4 years. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-023-01022-x.

show abstract

Section: Introductionmentioning

confidence: 78%

Section: Introductionmentioning

confidence: 78%

Responsiveness and Minimal Clinically Important Difference of the Infants and Toddlers Dermatology Quality of Life Questionnaire

Chernyshov,

Marron,

Koumaki

et al. 2023

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

show abstract

“…Use of the DLQI app is of course not limited to its possible use in teledermatology and it may be used during face-to-face consultations. It is important that further apps be developed to facilitate the use of other validated dermatology-specific HRQoL instruments, such as for those used in children with skin diseases (CDLQI [31][32][33] and InToDermQoL [34][35][36][37] ) and for disease-specific instruments.…”

Section: Discussionmentioning

confidence: 99%

Quality of life measurement in teledermatology. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Teledermatology

Chernyshov,

Finlay,

Tomas‐Aragones

et al. 2023

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Many events, including the COVID‐19 pandemic, have accelerated the implementation of teledermatology pathways within dermatology departments and across healthcare organizations. Quality of Life (QoL) assessment in dermatology is also a rapidly developing field with a gradual shift from theory to practice. The purpose of this paper organized jointly by the European Academy of Dermatology and Venereology (EADV) Task Force (TF) on QoL and patient‐oriented outcomes and the EADV TF on teledermatology is to present current knowledge about QoL assessment during the use of teledermatology approaches, including data on health‐related (HR) QoL instruments used in teledermatology, comparison of influence of different treatment methods on HRQoL after face‐to‐face and teledermatology consultations and to make practical recommendations concerning the assessment of QoL in teledermatology. The EADV TFs made the following position statements: HRQoL assessment may be an important part in most of teledermatology activities; HRQoL assessment may be easily and effectively performed during teledermatology consultations. It is especially important to monitor HRQoL of patients with chronic skin diseases during lockdowns or in areas where it is difficult to reach a hospital for face‐to‐face consultation; regular assessment of HRQoL of patients with skin diseases during teledermatology consultations may help to monitor therapy efficacy and visualize individual patient's needs; we recommend the use of the DLQI in teledermatology, including the use of the DLQI app which is available in seven languages; it is important to develop apps for dermatology‐specific HRQoL instruments for use in children (for example the CDLQI and InToDermQoL) and for disease‐specific instruments.

show abstract

“…17 It would be important to evaluate which interventions could decrease bullying of people with skin diseases and its adverse consequences, for example educational activities in schools, helping in gaining widespread easy access to psychological support may decrease negative psychosocial consequences. 18 Chernyshov et al 19 in their article titled 'Bullying in persons with skin diseases' aimed to examine the prevalence and nature of bullying in patients with skin diseases from six different countries and various age groups. I gladly recommend their excellent manuscript to Readers of the journal.…”

mentioning

confidence: 99%

Bullying and skin diseases

Szabó

2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

Sensitivity to treatment and score bands of the Infants and Toddlers Dermatology Quality of Life questionnaire

Cited by 6 publications

References 24 publications

Responsiveness and Minimal Clinically Important Difference of the Infants and Toddlers Dermatology Quality of Life Questionnaire

Responsiveness and Minimal Clinically Important Difference of the Infants and Toddlers Dermatology Quality of Life Questionnaire

Quality of life measurement in teledermatology. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Teledermatology

Bullying and skin diseases

Contact Info

Product

Resources

About